Biostar Pharma Grants Baheal Medical China Marketing Rights to Breast Cancer Drug

MT Newswires Live11-14

Beijing Biostar Pharmaceuticals (HKG:2563) granted Qingdao Baheal Medical (SHE:301015) unit Baheal Zhihe exclusive marketing rights in mainland China for its breast cancer drug Utidelone.

Under the agreement, Baheal Zhihe will exclusively market and promote Utidelone under the brand Youtidi to all medical institutions and pharmaceutical retail enterprises on the mainland.

Baheal will pay Biostar Pharma 50 million yuan in downpayment and sales milestone payments in the future, according to a Thursday disclosure with the Hong Kong Exchange.

Meanwhile, Chengdu Biostar Pharmaceuticals will take over marketing responsibilities for Utidelone in Hong Kong, Macau, and Taiwan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483875579?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483875579","market":"hk","top_or_hot":-1,"title":"Biostar Pharma Grants Baheal Medical China Marketing Rights to Breast Cancer Drug","media":"MT Newswires Live","content":"<html><body><p> Beijing Biostar Pharmaceuticals (HKG:2563) granted Qingdao Baheal Medical (SHE:301015) unit Baheal Zhihe exclusive marketing rights in mainland China for its breast cancer drug Utidelone.</p><p>Under the agreement, Baheal Zhihe will exclusively market and promote Utidelone under the brand Youtidi to all medical institutions and pharmaceutical retail enterprises on the mainland.</p><p>Baheal will pay Biostar Pharma 50 million yuan in downpayment and sales milestone payments in the future, according to a Thursday disclosure with the Hong Kong Exchange.</p><p>Meanwhile, Chengdu Biostar Pharmaceuticals will take over marketing responsibilities for Utidelone in Hong Kong, Macau, and Taiwan.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biostar Pharma Grants Baheal Medical China Marketing Rights to Breast Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiostar Pharma Grants Baheal Medical China Marketing Rights to Breast Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 19:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Beijing Biostar Pharmaceuticals (HKG:2563) granted Qingdao Baheal Medical (SHE:301015) unit Baheal Zhihe exclusive marketing rights in mainland China for its breast cancer drug Utidelone.Under the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"301015","symbol_name":"百洋医药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2483875579","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483875579","pubTimestamp":1731584923,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Beijing Biostar Pharmaceuticals  granted Qingdao Baheal Medical  unit Baheal Zhihe exclusive marketing rights in mainland China for its breast cancer drug Utidelone.Under the agreement, Baheal Zhihe will exclusively market and promote Utidelone under the brand Youtidi to all medical institutions and pharmaceutical retail enterprises on the mainland.Baheal will pay Biostar Pharma 50 million yuan in downpayment and sales milestone payments in the future, according to a Thursday disclosure with the Hong Kong Exchange.Meanwhile, Chengdu Biostar Pharmaceuticals will take over marketing responsibilities for Utidelone in Hong Kong, Macau, and Taiwan.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"301015":"百洋医药","02563":"华昊中天医药-B","BK0250":"批发"},"translate_title":"映泰制药授予百洋医疗乳腺癌药物中国营销权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301015":0.9,"02563":0.9},"content_text":"Beijing Biostar Pharmaceuticals (HKG:2563) granted Qingdao Baheal Medical (SHE:301015) unit Baheal Zhihe exclusive marketing rights in mainland China for its breast cancer drug Utidelone.Under the agreement, Baheal Zhihe will exclusively market and promote Utidelone under the brand Youtidi to all medical institutions and pharmaceutical retail enterprises on the mainland.Baheal will pay Biostar Pharma 50 million yuan in downpayment and sales milestone payments in the future, according to a Thursday disclosure with the Hong Kong Exchange.Meanwhile, Chengdu Biostar Pharmaceuticals will take over marketing responsibilities for Utidelone in Hong Kong, Macau, and Taiwan.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483875579"}